SenzaGen AB 2022 AR2
The report highlights SenzaGen's significant progress in 2022, marked by a 171% increase in consolidated net sales to SEK 41.8 million, driven by 77% organic growth and strategic acquisitions. A major milestone was achieved with the OECD approval of GARD®skin as a standard non-animal test method for skin sensitization, granting access to the entire toxicology market. Additionally, the company expanded its portfolio and consulting services through the acquisition of ToxHub. SenzaGen continues to align its operations with the UN Sustainable Development Goals, focusing on replacing animal testing with advanced in vitro technology.
Company: SenzaGen AB
Sector: Professional & technical services
Country: Sweden
Year: 2022
Type: AR2
Pages: 33
Back to company
SenzaGen AB
Annual Report
The report highlights SenzaGen's significant progress in 2022, marked by a 171% increase in consolidated net sales to SEK 41.8 million, driven by 77% organic growth and strategic acquisitions. A major milestone was achieved with the OECD approval of GARD®skin as a standard non-animal test method for skin sensitization, granting access to the entire toxicology market. Additionally, the company expanded its portfolio and consulting services through the acquisition of ToxHub. SenzaGen continues to align its operations with the UN Sustainable Development Goals, focusing on replacing animal testing with advanced in vitro technology.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees